Novigenix to Present Data on New Molecular Signature for Early Detection of Colon Cancer at ESMO 2019
Company Launches New Website to Enhance New Strategy Company to present at the Convergence of Oncology meeting in Lausanne LAUSANNE, SWITZERLAND - 07:00 CET, September 10, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature